Global Primary CD56+ NK Cells Market Growth 2023-2029
The global Primary CD56+ NK Cells market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Primary CD56+ NK Cells is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Primary CD56+ NK Cells is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Primary CD56+ NK Cells is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Primary CD56+ NK Cells players cover PBM, ATCC, STEMCEITM, Thermo Fisher Scientific, AllCells, ABM, 3H Biomedical, ProMab Biotechnologies and AcceGen, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Primary CD56+ Natural killer (NK) cells are the major effectors of the innate immune system and are important in host defense, cancer, and autoimmunity. CD56+ Natural Killer Cells are isolated from mononuclear cells by negative selection using immunomagnetic cell separation procedures.
LPI (LP Information)' newest research report, the “Primary CD56+ NK Cells Industry Forecast” looks at past sales and reviews total world Primary CD56+ NK Cells sales in 2022, providing a comprehensive analysis by region and market sector of projected Primary CD56+ NK Cells sales for 2023 through 2029. With Primary CD56+ NK Cells sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Primary CD56+ NK Cells industry.
This Insight Report provides a comprehensive analysis of the global Primary CD56+ NK Cells landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Primary CD56+ NK Cells portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Primary CD56+ NK Cells market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Primary CD56+ NK Cells and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Primary CD56+ NK Cells.
This report presents a comprehensive overview, market shares, and growth opportunities of Primary CD56+ NK Cells market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Custom Made
Bulk
Segmentation by application
Compound Screening
Immune Function Assay
Drug Discovery
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
PBM
ATCC
STEMCEITM
Thermo Fisher Scientific
AllCells
ABM
3H Biomedical
ProMab Biotechnologies
AcceGen
AMSBIO
Clinisciences
Creative Bioarray
iCell Bioscience
Shenzhen Kingfocus Biomedical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Primary CD56+ NK Cells market?
What factors are driving Primary CD56+ NK Cells market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Primary CD56+ NK Cells market opportunities vary by end market size?
How does Primary CD56+ NK Cells break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Please note: The report will take approximately 2 business days to prepare and deliver.